Page 24 - Read Online

55. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, HCC enhances doxorubicin’s death promoting effect by a p53 dependent
Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mechanism. J Hepatol 2009;50:969-79.
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. 71. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A,
Science 2004;306:269-71. Grazi GL, Bolondi L. Aberrant Notch3 and Notch4 expression in human
56. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, hepatocellular carcinoma. Liver Int 2007;27:997-1007.
Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. 72. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S,
Notch/gamma-secretase inhibition turns proliferative cells in intestinal Rodriguez-Carunchio L, Sole M, Thung S, Stanger BZ, Llovet JM. Notch
crypts and adenomas into goblet cells. Nature 2005;435:959-63. signaling is activated in human hepatocellular carcinoma and induces
57. Ambros V. Cell cycle-dependent sequencing of cell fate decisions tumor formation in mice. Gastroenterology 2012;143:1660-9.e7.
in Caenorhabditis elegans vulva precursor cells. Development 73. Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J.
1999;126:1947-56. Expression features of SOX9 associate with tumor progression and poor
58. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, prognosis of hepatocellular carcinoma. Diagn Pathol 2012;7:44.
Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, 74. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P,
de Sauvage F, Plowman G, Yan M. Inhibition of Dll4 signalling inhibits Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J,
tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7. Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor
59. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, in a randomized study of patients with Alzheimer disease. Neurology
Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, 2006;66:602-4.
Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, 75. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol
Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Ther 2013;139:95-110.
Kumar-Sinha C, Chinnaiyan AM. Functionally recurrent rearrangements 76. Tammam J, Ware C, Efferson C, O’Neil J, Rao S, Qu X, Gorenstein J,
of the MAST kinase and Notch gene families in breast cancer. Nat Med Angagaw M, Kim H, Kenifi c C, Kunii K, Leach KJ, Nikov G, Zhao J,
2011;17:1646-51. Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF,
60. Zender S, Nickeleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK.
El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Down-regulation of the Notch pathway mediated by a gamma-secretase
Plentz R, Zender L, Malek NP. A critical role for notch signaling in the inhibitor induces anti-tumour effects in mouse models of T-cell
formation of cholangiocellular carcinomas. Cancer Cell 2013;23:784-95. leukaemia. Br J Pharmacol 2009;158:1183-95.
61. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, 77. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K,
Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Jani JP, Hosea N, Sands M, Randolph S, Smeal T. Evaluation of selective
Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, gamma-secretase inhibitor PF-03084014 for its antitumor effi cacy and
Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, gastrointestinal safety to guide optimal clinical trial design. Mol Cancer
Frederick MJ. Integrative genomic characterization of oral squamous Ther 2010;9:1618-28.
cell carcinoma identifi es frequent somatic drivers. Cancer Discov 78. Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ,
2013;3:770-81. Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F,
62. Cui H, Kong Y, Xu M, Zhang H. Notch3 functions as a tumor suppressor L’Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB,
by controlling cellular senescence. Cancer Res 2013;73:3451-9. Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H,
63. Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC,
Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K. Huber HE. Characterization of Notch1 antibodies that inhibit signaling
Notch3 overexpression as potential therapeutic target in advanced stage of both normal and mutated Notch1 receptors. PLoS One 2010;5:e9094.
chemoresistant ovarian cancer. Am J Clin Pathol 2012;138:535-44. 79. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y,
64. Lu R, Gao H, Wang H, Cao L, Bai J, Zhang Y. Overexpression of Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ,
the Notch3 receptor and its ligand Jagged1 in human clinically Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P,
non-functioning pituitary adenomas. Oncol Lett 2013;5:845-51. Kadyk L, Yan M, Zha J, Callahan CA, Hymowitz SG, Siebel CW.
65. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Therapeutic antibody targeting of individual Notch receptors. Nature
Kunnimalaiyaan M, Chen H. Valproic acid activates notch-1 signaling 2010;464:1052-7.
and regulates the neuroendocrine phenotype in carcinoid cancer cells. 80. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, Scoggin S, Fu T,
Oncologist 2007;12:942-51. Vien L, Histen G, Zheng J, Martin-Hollister R, Duensing T, Singh S,
66. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Blacklow SC, Yao Z, Aster JC, Zhou BB. Modulation of Notch signaling
Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, by antibodies specifi c for the extracellular negative regulatory region of
Ball DW. Regulation of neuroendocrine differentiation in gastrointestinal NOTCH3. J Biol Chem 2008;283:8046-54.
carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 81. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P,
2005;90:4350-6. Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4
67. Ning L, Greenblatt DY, Kunnimalaiyaan M, Chen H. Suberoyl inhibits tumour growth by promoting non-productive angiogenesis.
bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis Nature 2006;444:1032-7.
in medullary thyroid carcinoma cells. Oncologist 2008;13:98-104. 82. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R,
68. Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of
Radtke F, Heim MH. Inducible inactivation of Notch1 causes nodular Dll4-mediated signaling induces proliferation of immature vessels and
regenerative hyperplasia in mice. Hepatology 2005;41:487-96. results in poor tissue perfusion. Blood 2007;109:4753-60.
69. Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D’Adamo S, 83. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M,
Cipone M, Chieco P, Gramantieri L, Bolondi L. Notch3 inhibition Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X,
enhances sorafenib cytotoxic efficacy by promoting GSK3b Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J. A notch1
phosphorylation and p21 down-regulation in hepatocellular carcinoma. ectodomain construct inhibits endothelial notch signaling, tumor growth,
Oncotarget 2013;4:1618-31. and angiogenesis. Cancer Res 2008;68:4727-35.
70. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, 84. Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, Di Serio C,
Ramazzotti E, Marcu KB, Bolondi L. Selective ablation of Notch3 in Di Serio C, Prudovsky I, Maciag T. Soluble Jagged 1 represses the

Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015 17